| Completed | 3 | 1369 | RoW | JT001, VV116, Placebo | Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH | Mild to Moderate COVID-19 | 02/23 | 02/23 | | |
NCT05224960: Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) |
|
|
| Recruiting | 2 | 140 | RoW | UC-MSCs, Placebo(solution without UC-MSCs) | Beijing 302 Hospital, Chinese PLA General Hospital, Shanghai Changzheng Hospital, LanZhou University, Jin Yin-tan Hospital, Hainan Hospital of Chinese PLA General Hospital, Vcanbio Cell and Gene Engineering Corp., Ltd., Third Affiliated Hospital, Sun Yat-Sen University, Xinjiang Kashi Area Number 1 Hospital | Decompensated Cirrhosis | 06/25 | 06/27 | | |
NCT06038916: To Evaluate the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome |
|
|
| Recruiting | 1/2 | 60 | RoW | STSA-1002 Injection Placebo, STSA-1002 Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Acute Respiratory Distress Syndrome | 08/25 | 09/26 | | |
